Aligos Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue from collaborations | $334 | $9,338 |
| Revenue from customers | 3,611 | 6,191 |
| Operating expenses: | ||
| Research and development | 70,269 | 73,040 |
| General and administrative | 22,830 | 30,616 |
| Total operating expenses | 93,099 | 103,656 |
| Loss from operations | (89,154) | (88,127) |
| Interest and other income, net | 4,406 | 3,412 |
| Change in fair value of common warrants | (46,132) | (2,169) |
| Loss before income tax | (130,880) | (86,884) |
| Income tax provision | (331) | (795) |
| Net loss | (131,211) | (87,679) |
| Other comprehensive (loss) income: | ||
| Unrealized gain on available-for-sale securities | 9 | 96 |
| Unrealized (loss) gain on pension plans | (103) | 48 |
| Other comprehensive (loss) income | (94) | 144 |
| Comprehensive loss | $(131,305) | $(87,535) |
| Net loss per share, basic and diluted | $(20.94) | $(34.20) |
| Weighted average shares of common stock, basic and diluted | 6,264,612 | 2,563,470 |
Consolidated Statements of Changes in
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.